What if the solutions to the greatest unsolved medical problems of our time had already been evolved in nature, embodied as molecules laying in wait to be mined?
What if revolutionary discoveries in emerging scientific fields from gigascale DNA sequencing to artificial intelligence and synthetic biology had advanced, such that we finally had a way to mine the biosphere and bring its powerful solutions to patients in need?
Our answers to these questions drive the passion and mission at LifeMine Therapeutics.
LifeMine is the first company to massively scale the genomic discovery of powerful new drug modalities from eukaryotic microbes. Our integrated, genomically-enabled drug discovery engine is poised to deliver a pipeline of medicines that will conquer previously unconquerable human diseases.
The company has succeeded in hacking an evolutionary code in biosynthetic genes, creating a springboard for rapid discovery of naturally inspired drugs that function in unexpected ways. These medicines transcend the standard playbook of drug design.
LifeMine grew out of visionary founder Gregory Verdine’s life passion to discover and commercialize new drug modalities.
For thousands of years, people have discovered medicines from fungi by brewery. This approach has led to transformative medicines that saved millions of lives and have altered the course of medical history.
Drug discovery by brewery proved to be difficult and time-consuming, leaving the field in search of a disruptive technological solution. Our genomically-enabled drug discovery engine is precisely that solution, dramatically accelerating the search for nature’s breakthrough drugs.
At LifeMine, genomicists, bioinformaticians and microbiologists identify new evolutionary solutions for disease intervention; natural products chemists access the natural molecules that inspire our drug discovery efforts; biologist and chemist drug hunters craft these into disruptively innovative medicines, and translational medical scientists bring the life-saving solutions forward into patients in need.
If you love working with the best people in the field, expanding your limits, and want to write the future story of medicine, then come join our team at LifeMine.

Press Releases
LifeMine Therapeutics Appoints Nobel Laureate William G. Kaelin Jr., M.D., to Board of Directors
LifeMine Therapeutics Announces $50 Million Series B Financing
LifeMine Powers Drug Discovery Team to Search the Biosphere for Nature’s Evolved Solutions to Intractable Therapeutic Challenges
LifeMine Therapeutics Launches with $55 Million Series A Financing
In the News
Media Contact:
media@lifeminetx.com
617.665.5000
